Ovid Therapeutics (OVID)
(Delayed Data from NSDQ)
$1.15 USD
-0.02 (-1.71%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $1.16 +0.01 (0.87%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Price, Consensus and EPS Surprise
OVID 1.15 -0.02(-1.71%)
Will OVID be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for OVID based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for OVID
Ovid Therapeutics (OVID) Upgraded to Buy: Here's Why
Ovid Therapeutics (OVID) Q2 Earnings and Revenues Surpass Estimates
OVID: What are Zacks experts saying now?
Zacks Private Portfolio Services
Mersana Therapeutics, Inc. (MRSN) Reports Q2 Loss, Misses Revenue Estimates
Cardiff Oncology (CRDF) Reports Q2 Loss, Tops Revenue Estimates
BioXcel Therapeutics, Inc. (BTAI) Reports Q2 Loss, Tops Revenue Estimates
Other News for OVID
Meg Alexander Takes on Expanded Role as President and COO at Ovid Therapeutics, Strengthening Leadership for Future Growth
Ovid Therapeutics Elevates Meg Alexander to President and COO
Ovid Therapeutics appoints Alexander as President, COO
Stoke Therapeutics: The First Gene Therapy For Dravet Syndrome
Ovid Therapeutics to Present at Upcoming September Investor Conferences